<--- Back to Details
First PageDocument Content
Cytokines / Immunosuppressants / Medicine / Autoimmune diseases / Treatment of multiple sclerosis / Natalizumab / Glatiramer acetate / Fingolimod / Interferon beta-1a / Immunology / Immune system / Multiple sclerosis
Date: 2015-04-22 23:39:46
Cytokines
Immunosuppressants
Medicine
Autoimmune diseases
Treatment of multiple sclerosis
Natalizumab
Glatiramer acetate
Fingolimod
Interferon beta-1a
Immunology
Immune system
Multiple sclerosis

Add to Reading List

Source URL: www.pbs.gov.au

Download Document from Source Website

File Size: 91,94 KB

Share Document on Facebook

Similar Documents

Medicine / Medical research / Immunology / Clinical research / Multiple sclerosis / Immunosuppressants / Design of experiments / Medical ethics / Fingolimod / Management of multiple sclerosis / Interferon beta-1a / Clinical trial

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

DocID: 1qn6Z - View Document

Stellungnahme der AkdÄ zur Nutzenbewertung von Fingolimod (neues Anwendungsgebiet)

DocID: 1n48S - View Document

Rote-Hand-Brief zu Gilenya® (Fingolimod)

DocID: 1h06f - View Document

Autoimmune diseases / Medicine / Immunosuppressants / Neurological disorders / Treatment of multiple sclerosis / Glatiramer acetate / Natalizumab / Mitoxantrone / Fingolimod / Multiple sclerosis / Immunology / Immune system

Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators

DocID: 1fWCE - View Document

Bijlage bij email betreffende vergoeding fingolimod juliArtikel uit MenSen nr. 4 Samenvatting aanvullende voorwaarden zoals is overeengekomen op 4 juni 2013 met CVZ, VWS, zorgverzekeraars, MS Vereniging Nederland,

DocID: 1ea9n - View Document